131 related articles for article (PubMed ID: 33394756)
21. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
[TBL] [Abstract][Full Text] [Related]
24. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
Lee SE; Lee B; Hong M; Song JY; Jung K; Lira ME; Mao M; Han J; Kim J; Choi YL
Mod Pathol; 2015 Apr; 28(4):468-79. PubMed ID: 25234288
[TBL] [Abstract][Full Text] [Related]
26. Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
Zhang Y; Yu M; Yuan M; Chen R; Huang MJ
Clin Lung Cancer; 2020 Mar; 21(2):e78-e83. PubMed ID: 31722815
[No Abstract] [Full Text] [Related]
27. Novel
Deland L; Keane S; Bontell TO; Fagman H; Sjögren H; Lind AE; Carén H; Tisell M; Nilsson JA; Ejeskär K; Sabel M; Abel F
Cancer Genomics Proteomics; 2022; 19(6):711-726. PubMed ID: 36316040
[TBL] [Abstract][Full Text] [Related]
28. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
30. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
31. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
[TBL] [Abstract][Full Text] [Related]
32. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
33. Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases.
Salifu EY; Issahaku AR; Agoni C; Ibrahim MAA; Manimbulu N; Soliman MES
Cell Biochem Biophys; 2022 Mar; 80(1):11-21. PubMed ID: 35040089
[TBL] [Abstract][Full Text] [Related]
34. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
35. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
36. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
Gainor JF; Shaw AT
Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
[TBL] [Abstract][Full Text] [Related]
37. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
[TBL] [Abstract][Full Text] [Related]
38. Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma.
Nakano Y; Tomiyama A; Kohno T; Yoshida A; Yamasaki K; Ozawa T; Fukuoka K; Fukushima H; Inoue T; Hara J; Sakamoto H; Ichimura K
Brain Tumor Pathol; 2019 Jan; 36(1):14-19. PubMed ID: 30350109
[TBL] [Abstract][Full Text] [Related]
39. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
40. The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.
Cerrato A; Visconti R; Celetti A
Mol Cancer; 2018 Feb; 17(1):46. PubMed ID: 29455670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
